Recent Quotes (30 days)

You have no recent quotes
chg | %

GeneNews Ltd  

(Public, TSE:GEN)   Watch this stock  
Find more results for GEN
-0.005 (-2.86%)
Jun 24 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.16 - 0.18
52 week 0.01 - 0.37
Open 0.17
Vol / Avg. 248,149.00/477,634.00
Mkt cap 10.02M
P/E     -
Div/yield     -
EPS -0.18
Shares 62.74M
Beta 8.68
Inst. own     -
Aug 12, 2016
Q2 2016 GeneNews Ltd Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 15, 2016
Q1 2016 GeneNews Ltd Earnings Release
May 27, 2016
Q4 2015 GeneNews Ltd Earnings Release

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -2046.63% -1846.70%
Operating margin -2046.62% -1883.91%
EBITD margin - -892.90%
Return on average assets -603.36% -343.37%
Return on average equity - -3136.17%
Employees 4 -
CDP Score - -


445 Apple Creek Blvd Unit 220
+1-905-7392030 (Phone)
+1-905-7392031 (Fax)

Website links


GeneNews Limited (GeneNews) is a Canada-based molecular diagnostics company. GeneNews is focused to become a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. Company is also focused to identify and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with personalized clinical intelligence and actionable information to improve health outcomes through the early diagnosis of disease. The Company offers services like: ColonSentry, which is a blood test that can assess a patient's current risk of having colorectal cancer. The test is not considered a replacement for colonoscopy, but rather a more convenient step in determining early warning signs of colon cancer, A 3-Dimensional Approach to Detecting & Treating Cancer; that provide physicians with clinical intelligence through early detection of disease and guiding treatment.

Officers and directors

James R. Howard-Tripp Executive Chairman of the Board
Leslie Auld Chief Financial Officer, Treasurer, Director
Karl Wassmann Executive Vice President - US Corporate Development
Heinrich Dreismann Ph.D. Lead Director
Age: 62
Harry A. Glorikian Independent Director
Garth A. C. MacRae Independent Director
Age: 81
Rory B. Riggs Independent Director
Age: 62